# Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

> **NCT03433469** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of California, San Francisco** · enrollment: 27 (actual)

## Conditions studied

- Stage I Non-Small Cell Lung Cancer
- Stage IA Non-Small Cell Lung Cancer
- Stage IB Non-Small Cell Lung Cancer
- Stage II Non-Small Cell Lung Cancer
- Stage IIA Non-Small Cell Lung Cancer
- Stage IIB Non-Small Cell Lung Cancer
- Stage IIIA Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Osimertinib
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT03433469
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-07-31
- **Primary completion:** 2023-01-31
- **Final completion:** 2027-09-30
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2026-03-30

## Collaborators

- AstraZeneca

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03433469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03433469, "Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03433469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*